跳至主要内容
临床试验/NCT00482690
NCT00482690终止不适用

Analysis of Aldehyde Biomarkers of Exposure and Host Response

University of Nebraska1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2005年8月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
35
试验地点
1
主要终点
Aldehyde Biomarkers

研究概览

简要总结

Analysis of aldeyde biomarkers of exposure and host response The purpose of this prospective, open-label, clinical trial is to establish the feasibility and validity of exhaled breath condensate (EBC) biomarkers for use in studies designed to evaluate harm reduction strategies of smoking. This will be accomplished by measuring selected markers in EBC believed related to the pathogenesis of lung disease before and after a smoking cessation intervention.

详细描述

Twenty subjects will be accrued in three groups based on smoking habit: 10-20, 20-30 and >30 cigarettes/day. Eligibility criteria include male and female cigarette smokers ≥19 years of age, who are able to give informed consent, able to exhale into Eco Screen instrument for 15-20 minutes. All must be willing to make a serious quit attempt and be willing to use nicotine replacement therapy.

Subjects will be excluded if any of the following are present: regular use of anti-inflammatory medication; presence of any inflammatory disease of the respiratory tract including moderate or worse COPD (FEV1 < 80% predicted and FEV1/FVC ratio < 0.7). Subjects with normal lung function who meet criteria for diagnosis of chronic bronchitis will be excluded. Subjects with stable medical conditions, excluding inflammatory lung disease, will be permitted to participate, providing anti-inflammatory therapies are not used regularly and providing there has been no change in their clinical status in the two months prior to beginning the study.

Upon entering into the study, subjects will establish a quit date and will be treated with nicotine replacement therapy (NRT) products based on individual preference and will receive smoking cessation counseling. They will then be seen at 12 visits over the course of 25 weeks.

Evaluations will include vital signs, interval smoking history, food frequency questionnaire, exhaled carbon monoxide, blood drawn for chemistry and CBC, peripheral blood harvested and serum aliquoted and saved for future biochemical analysis, urine sample for isoprostane, pregnancy test for females, and exhaled breath condensate. Some visits may also include spirometry with and with out bronchodilators, 24 hour urine collections for NNAL and NNAL-glc quantification, health status assessed using St. George's Respiratory Questionnaire, the Functional Assessment of Chronic Illness Therapy - Fatigue, the Leicester Cough Questionnaire, the Clinical COPD Questionnaire and smoking related symptoms assessed using the Breathlessness, Cough, and Sputum Scale.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Smokers of at least 5 pack years;
  • Stable smoking habit for 3 months;
  • Willing to make a serious quit attempt;
  • Able to use nicotine replacement therapy

排除标准

  • Regular use of anti-inflammatory medication
  • Inflammatory lung disease
  • Unstable medical condition

研究组 & 干预措施

Nicotine replacement therapy (NRT)

Experimental

open label NRT self comparator design

干预措施: nicotine polacrilex (Drug)

Nicotine replacement therapy (NRT)

Experimental

open label NRT self comparator design

干预措施: nicotine transdermal system (Drug)

Nicotine replacement therapy (NRT)

Experimental

open label NRT self comparator design

干预措施: nicotine inhaler (Drug)

结局指标

主要结局

Aldehyde Biomarkers

时间窗: Study was terminated at an interim analysis for futility

Aledhydes were assessed in exhaled breath condensate by mass spec and chemical assay.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验